Emcure Pharma reduces Poviztra starting dose price by 55% in India
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Poviztra is a second brand of Wegovy
Subscribe To Our Newsletter & Stay Updated